Reports Summarize Prostate Cancer Findings from Memorial Sloan-Kettering Cancer Center (Lesion Dosimetry for [<superscript>177</superscript>lu]Lu-psma-617 Radiopharmaceutical Therapy Combined With Stereotactic Body Radiotherapy In Patients With Oligometastat.
In: Clinical Trials Week, 2024-01-29, S. 756-756
serialPeriodical
Zugriff:
A recent study conducted at the Memorial Sloan-Kettering Cancer Center in New York City explored the feasibility of combining radio-pharmaceutical therapy (RPT) with stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic castration-sensitive prostate cancer. The study involved six patients with prostate-specific membrane antigen (PSMA)-positive oligometastases who received two cycles of RPT followed by SBRT. The combination therapy was completed without complications, and no grade 3+ toxicities were observed. The study found that combining RPT and SBRT may be an effective method for delivering meaningful doses to oligometastatic disease while minimizing exposure to normal tissues. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Reports Summarize Prostate Cancer Findings from Memorial Sloan-Kettering Cancer Center (Lesion Dosimetry for [<superscript>177</superscript>lu]Lu-psma-617 Radiopharmaceutical Therapy Combined With Stereotactic Body Radiotherapy In Patients With Oligometastat.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2024-01-29, S. 756-756 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|